Destiny Pharma Significant clinical and commercial opportunity of NTCD-M3 confirmed by positive data from US research study and new market research

/in

Significant clinical and commercial opportunity of NTCD-M3 confirmed by positive data from US research study and new market research US Department of Veterans Affairs study confirms the potential of NTCD-M3 as a novel treatment to prevent the recurrence of CDI that can be used alongside all standard-of-care antibiotic treatments US and European market research underpins clinical […]

Read more

Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD

/in

Top-line Data Expected in the Third Quarter of 2022 LONDON and RALEIGH, N.C., Jan. 24, 2022 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces it has completed patient enrollment with more than 800 subjects randomized in the ENHANCE-2 trial, evaluating […]

Read more

Destiny Pharma Lancet Report

/in

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Important Lancet report highlights growing threat of Antimicrobial Resistance with over one million deaths per year Destiny Pharma’s XF platform is delivering effective drug candidates that also address the threat of AMR Brighton, United Kingdom, 21 January 2022 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative […]

Read more

Amber Implants Closes US$10 M Series A Financing

/in

The Hague, Netherlands, 19 January 2022: Amber Implants, an innovative medical technology company developing next generation spinal implants for spinal injuries, today announces the successful closing of its US$10 million Series A Financing in 2021. The round was co-led by the founders and existing venture capital investors, with participation from angel investors and non-dilutive government funding. […]

Read more

Egetis concludes that demonstrating treatment effects on T3 levels in MCT8-deficiency could provide a basis for marketing approval for Emcitate® in the US

/in

Emcitate® (tiratricol) is the first potential treatment of MCT8 deficiency, a rare genetic disease with high unmet medical need and no available treatment. Egetis will host a webcast today at 15:00 CET (9:00am ET) Stockholm, Sweden, January 18, 2022 – Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) (the “Company”) today announced that in recent regulatory interactions, […]

Read more
© Optimum Strategic Communications.